Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
0.6199
+0.0341 (5.82%)
At close: Apr 28, 2025, 4:00 PM
0.6262
+0.0063 (1.02%)
Pre-market: Apr 29, 2025, 7:31 AM EDT
Adicet Bio Employees
Adicet Bio had 152 employees as of December 31, 2024. The number of employees increased by 9 or 6.29% compared to the previous year.
Employees
152
Change (1Y)
9
Growth (1Y)
6.29%
Revenue / Employee
n/a
Profits / Employee
-$770,539
Market Cap
51.26M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 152 | 9 | 6.29% |
| Dec 31, 2023 | 143 | 11 | 8.33% |
| Dec 31, 2022 | 132 | 46 | 53.49% |
| Dec 31, 2021 | 86 | 4 | 4.88% |
| Dec 31, 2020 | 82 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
ACET News
- 15 hours ago - Adicet Bio Announces Oral Presentation Highlighting Preclinical ADI-270 Data at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Business Wire
- 12 days ago - Adicet Bio Appoints Michael Grissinger to the Board of Directors - Business Wire
- 4 weeks ago - Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Adicet Bio to Participate in 2025 Canaccord Genuity Horizons in Oncology Virtual Conference - Business Wire
- 7 weeks ago - Adicet Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Company Progress - Business Wire
- 2 months ago - Adicet Announces Poster Presentations Highlighting ADI-270 Data at the Society for Immunotherapy of Cancer (SITC) 2025 Spring Scientific Meeting - Business Wire
- 2 months ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Systemic Sclerosis (SSc) - Business Wire
- 2 months ago - Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of Refractory Systemic Lupus Erythematosus (SLE) with Extrarenal Involvement - Business Wire